Phaseline

Companies › Pliant Therapeutics

Pliant Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PLN-101095–Phase 1Advanced or Metastatic Solid TumorJun 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06270706PLN-101095Phase 1Advanced or Metastatic Solid TumorOncologyJun 2030

From the company's SEC filings

Cash and short-term investments of $158m on 2026-06-30; operating cash outflow about $65m a year; runway about 29 months at that burn, to Dec 2028

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.